"Without controls in place as reliable as the set of immune receptor templates we have developed to eliminate any PCR bias, standardization of a kit would be quite difficult," explained Adaptive co-founder Dr. Harlan Robins.
Adaptive has several other assays being prepped for clinical use in oncology/hematology, immunology, and infectious diseases.
The company remains committed to expanding the use of its platforms as diagnostic tools in clinical trials and as fee-for-service research whereby academic and industry collaborators can incorporate studies of B and T-cell immune repertoire status into their studies.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation (
), headquartered in
, is pioneering the field of genomic immunology. The company's core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research and clinical communities as well as the biopharmaceutical industry. Adaptive operates a state-of-the-art high throughput centralized laboratory in
that is CLIA certified and will be accepting clinical samples in 2013. Its flagship commercial product, immunoSEQ (
), uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system's defense against disease – with unprecedented depth and specificity. In 2013, the company will introduce clonoSEQ (
),a clinical assay to measure and monitor minimal residual disease (MRD) in a range of blood-based cancers that is significantly more sensitive than today's most common tests. All of Adaptive Biotechnologies' assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface.
SOURCE Adaptive Biotechnologies Corporation